Why Is ACADIA PHARMACEUTICA (ACAD) Stock Down Today?

Why ACAD stock is down today

ACADIA Pharmaceuticals stock closed down 12.78% at $22.18 on September 24, marking its worst single-day decline in two years. The drop followed the release of Phase 3 topline data for its Alzheimer’s psychosis drug, which failed to meet its primary endpoint. Analysts including Citi and Goldman Sachs revised their outlooks and price targets in response, signaling reduced confidence in the drug’s potential.

What Happened

ACADIA Pharmaceuticals announced the results of its Phase 3 trial for remlifanserin, a drug targeting Alzheimer’s disease psychosis. The trial did not achieve its primary goal, which led to immediate market concern. A Form 8-K filed with the SEC disclosed the results under Regulation FD, triggering a rapid sell-off. Citigroup analyst Yigal Nochomovitz cut the price target for ACAD to $33 from $40 and maintained a Buy rating, while Goldman Sachs reiterated its Sell rating following the trial miss. TD Cowen also kept its existing rating but did not adjust its price target. The stock’s decline reflects the market’s reaction to the underwhelming clinical data and the subsequent analyst revisions.

What The Data Shows

The stock has declined 13.0% over the past eight sessions, from $26.88 to $23.39. On September 24, it printed nine fresh 52-week lows. Insider selling has been notable in recent months, with three executives, Mark C. Schneyer, Elizabeth H.Z. Thompson, and James Kihara, selling shares totaling $1.3 million in the last 90 days. The stock currently trades within its 52-week range of $19.69 to $30.96 and has a market cap of $4.5 billion. With a beta of 0.86, it is less volatile than the broader market. The recent trial outcome and analyst revisions have amplified the downward pressure on the stock.

What To Watch

The company has no scheduled earnings date in the immediate future. Investors will need to monitor coverage breadth and any further analyst commentary for shifts in sentiment.